Ian Ratcliffe is listed as an executive officer, director, and promoter on 13 SEC Form D filings by 5 issuers between Nov 2009 and Dec 2020: Mitra RxDx, Inc. (Woburn, MA — other health care — 2016–2019; $43.8M reported sold to 19 investors), Agilis Biotherapeutics, Inc. (Cambridge, MA — biotechnology — 2017; $12.7M reported sold to 27 investors), Stemgent, Inc. (Cambridge, MA — biotechnology — 2009–2012; $11.3M reported sold to 8 investors), NanoView Biosciences, Inc. (Boston, MA — biotechnology — 2018–2020; $9M reported sold to 4 investors) and ENZYMATICS INC (Beverly, MA — industry reported as "Other" — 2013; $3.79M reported sold to 8 investors).
What this means A repeat sponsor — 5 separate companies raised money with this person listed as executive officer, director, and promoter, over about 11 years. Across those companies the filings report $80.6M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 13 public filings for Ian Ratcliffe and found 12 differences, 1 worth asking the sponsor about: Form D filed 67 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.